CN105283075A - 抗失巢凋亡胎盘干细胞及其应用 - Google Patents

抗失巢凋亡胎盘干细胞及其应用 Download PDF

Info

Publication number
CN105283075A
CN105283075A CN201380072901.5A CN201380072901A CN105283075A CN 105283075 A CN105283075 A CN 105283075A CN 201380072901 A CN201380072901 A CN 201380072901A CN 105283075 A CN105283075 A CN 105283075A
Authority
CN
China
Prior art keywords
ncbigeneidno
anoikis
cell
placental stem
arpscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380072901.5A
Other languages
English (en)
Chinese (zh)
Inventor
张小葵
斯图尔特·阿博特
瓦内萨·沃斯基纳里安-贝尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to CN202110724603.6A priority Critical patent/CN113481164A/zh
Publication of CN105283075A publication Critical patent/CN105283075A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
CN201380072901.5A 2012-12-14 2013-12-13 抗失巢凋亡胎盘干细胞及其应用 Pending CN105283075A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110724603.6A CN113481164A (zh) 2012-12-14 2013-12-13 抗失巢凋亡胎盘干细胞及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737498P 2012-12-14 2012-12-14
US61/737,498 2012-12-14
PCT/US2013/074892 WO2014093753A1 (en) 2012-12-14 2013-12-13 Anoikis resistant placental stem cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110724603.6A Division CN113481164A (zh) 2012-12-14 2013-12-13 抗失巢凋亡胎盘干细胞及其应用

Publications (1)

Publication Number Publication Date
CN105283075A true CN105283075A (zh) 2016-01-27

Family

ID=50934980

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380072901.5A Pending CN105283075A (zh) 2012-12-14 2013-12-13 抗失巢凋亡胎盘干细胞及其应用
CN202110724603.6A Pending CN113481164A (zh) 2012-12-14 2013-12-13 抗失巢凋亡胎盘干细胞及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110724603.6A Pending CN113481164A (zh) 2012-12-14 2013-12-13 抗失巢凋亡胎盘干细胞及其应用

Country Status (7)

Country Link
US (1) US20150307879A1 (https=)
EP (2) EP2938196B1 (https=)
JP (5) JP2016502844A (https=)
CN (2) CN105283075A (https=)
AU (1) AU2013359076A1 (https=)
CA (1) CA2895106C (https=)
WO (1) WO2014093753A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107475419A (zh) * 2017-09-22 2017-12-15 浙江大学 Kndc1基因及其表达产物在卵巢癌检测中的应用
CN110129321A (zh) * 2019-07-08 2019-08-16 江苏医药职业学院 降低LSG1基因表达的siRNA、重组载体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970883T3 (da) * 2013-03-14 2021-08-09 Celularity Inc Forbedrede placenta stamceller og bruge deraf

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101862315A (zh) * 2009-04-17 2010-10-20 中国医学科学院血液病医院（血液学研究所） 双取代苯基双胍诱导恶性肿瘤细胞失巢凋亡的用途
US20120171161A1 (en) * 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
WO2012092485A1 (en) * 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
US6384105B1 (en) 1999-04-16 2002-05-07 William Marsh Rice University Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol)
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
EP3246396B1 (en) 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
EP2316919B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
DK1957633T3 (en) 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
CA2633980A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
PT2471904T (pt) * 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
US20100305188A1 (en) * 2007-10-03 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of regulating the proliferation of cell
JP2013507989A (ja) * 2009-10-26 2013-03-07 アボット・ラボラトリーズ 非小細胞肺癌の予後に関連する染色体異常の検出
KR101874463B1 (ko) * 2009-10-31 2018-08-02 뉴 월드 레보러토리즈 인코포레이티드. 세포의 재프로그램화 방법 및 이의 용도
LT2556145T (lt) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
DK2970883T3 (da) * 2013-03-14 2021-08-09 Celularity Inc Forbedrede placenta stamceller og bruge deraf

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101862315A (zh) * 2009-04-17 2010-10-20 中国医学科学院血液病医院（血液学研究所） 双取代苯基双胍诱导恶性肿瘤细胞失巢凋亡的用途
US20120171161A1 (en) * 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
WO2012092485A1 (en) * 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
US20120230959A1 (en) * 2010-12-31 2012-09-13 Abbot Stewart Enhancement of placental stem cell potency using modulatory rna molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DANIELLE S.W. BENOIT等: "Integrin-linked kinase production prevents anoikis in human mesenchymal stem cells", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A》 *
ERIN N HOWE等: "Targets of miR-200c mediate suppression of cell motility and anoikis resistance", 《BREAST CANCER RESEARCH》 *
XIANG YU等: "miR-125b Is an Adhesion-Regulated microRNA that Protects Mesenchymal Stem Cells from Anoikis", 《STEM CELLS》 *
XIAOFANG WANG等: "Inhibition of Caspase-mediated Anoikis Is Critical for Basic Fibroblast Growth Factor-sustained Culture of Human Pluripotent Stem Cells", 《JOURNAL OF BIOLOGICAL CHEMISTRY》 *
朱少芳等: "人胎盘间充质干细胞生物学特性和抗凋亡细胞因子的分泌", 《中国组织工程研究与临床康复》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107475419A (zh) * 2017-09-22 2017-12-15 浙江大学 Kndc1基因及其表达产物在卵巢癌检测中的应用
CN110129321A (zh) * 2019-07-08 2019-08-16 江苏医药职业学院 降低LSG1基因表达的siRNA、重组载体及其应用
CN110129321B (zh) * 2019-07-08 2021-10-15 江苏医药职业学院 降低LSG1基因表达的siRNA、重组载体及其应用

Also Published As

Publication number Publication date
CN113481164A (zh) 2021-10-08
JP2019068814A (ja) 2019-05-09
WO2014093753A1 (en) 2014-06-19
JP2022160451A (ja) 2022-10-19
NZ709113A (en) 2020-11-27
US20150307879A1 (en) 2015-10-29
CA2895106A1 (en) 2014-06-19
JP2016502844A (ja) 2016-02-01
AU2013359076A1 (en) 2015-07-02
EP2938196A4 (en) 2016-10-26
JP2024153631A (ja) 2024-10-29
EP2938196B1 (en) 2019-04-03
EP2938196A1 (en) 2015-11-04
JP2021045133A (ja) 2021-03-25
CA2895106C (en) 2023-01-24
EP3556215A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
US8969315B2 (en) Enhancement of placental stem cell potency using modulatory RNA molecules
JP2022166249A (ja) ヒト胎盤灌流液由来の血管形成細胞
US20230081199A1 (en) Enhanced placental stem cells and uses thereof
JP2024153631A (ja) アノイキス抵抗性胎盤幹細胞及びその使用
HK40013725A (en) Anoikis resistant placental stem cells and uses thereof
HK40051320A (en) Enhanced placental stem cells and uses thereof
NZ709113B2 (en) Anoikis resistant placental stem cells and uses thereof
CN101326280A (zh) 使用胎盘干细胞的免疫调节

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160127